Although
3,4-dihydroxyphenylalanine (
levodopa) is the gold-standard treatment for
Parkinson's disease, it can lead to disabling
dyskinesias. Previous work demonstrated that
nicotine reduces
levodopa-induced
dyskinesias (LIDs) in several parkinsonian animal models. The goal of this study was to determine whether the duration of
nicotine administration affects its ability to reduce LIDs in
levodopa-primed and
levodopa-naíve monkeys and also to test whether tolerance develops to the beneficial effects of
nicotine. Monkeys were injected with
MPTP (1.9-2.0 mg/kg subcutaneously) over 3 to 5 months until
parkinsonism developed.
Nicotine (300 μg/mL) was administered in
drinking water (over 4-6 months) to
levodopa-primed or
levodopa-naíve monkeys, with
levodopa/
carbidopa (10/2.5 mg/kg) gavaged twice daily. One set of
MPTP-lesioned monkeys (n = 23) was first gavaged with
levodopa and subsequently received
nicotine 4 weeks later, when
dyskinesias plateaued, or 8 weeks later, when
dyskinesias were established. A 60% to 70% decrease in LIDs was observed after several weeks of
nicotine treatment in both groups. A second set of monkeys (n = 26) received
nicotine 8 or 2 weeks before
levodopa. In the 8-week
nicotine pretreatment group, there was an immediate reduction in LIDs, which plateaued at 60% to 70%. In the 2-week
nicotine pretreatment group, there were initial small decreases in LIDs, which plateaued at 60% to 70% several weeks later. Thus,
nicotine pretreatment and
nicotine post-treatment were similarly efficacious in reducing LIDs. The beneficial effect of
nicotine persisted throughout the study (17-23 weeks).
Nicotine did not worsen
parkinsonism. These data suggest that
nicotine treatment has potential as a successful antidyskinetic
therapy for patients with
Parkinson's disease.